We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PROTEONOMIX, INC.'s CEO to Present at Investor Summit 2012
News

PROTEONOMIX, INC.'s CEO to Present at Investor Summit 2012

PROTEONOMIX, INC.'s CEO to Present at Investor Summit 2012
News

PROTEONOMIX, INC.'s CEO to Present at Investor Summit 2012

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PROTEONOMIX, INC.'s CEO to Present at Investor Summit 2012"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The company will be presenting at the Investor Summit 2012 on February 1, 2012, sponsored by Merriman Capital at the Intercontinental Time Square Hotel in New York City.

Michael Cohen, President of the Company, stated: "We thank Merriman Capital for the opportunity address the investment community regarding the Company's UMK 121 technology. The Company will address the use of the technology in the emerging markets, particularly in Africa where large numbers of cases of severe cirrhosis and accompanying End Stage Liver Disease exist."

Mr. Cohen continued, "Our UMK-121 pharmaceutical therapy is advancing toward its first clinical trial in ESLD ("End Stage Liver Disease") patients. In addition we intend to highlight other parts of our company of interest to the investment community including our Proteoderm cosmeceutical subsidiary and StromaCel."

Advertisement